S N Lo

List of Publications by Year in descending order

187 papers	9,603 citations	61984 43 h-index	42399 92 g-index
192 all docs	192 docs citations	192 times ranked	11508 citing authors

#	Article	IF	Citations
1	Intensity of Continuous Renal-Replacement Therapy in Critically Ill Patients. New England Journal of Medicine, 2009, 361, 1627-1638.	27.0	1,288
2	An observational study fluid balance and patient outcomes in the randomized evaluation of normal vs. augmented level of replacement therapy trial*. Critical Care Medicine, 2012, 40, 1753-1760.	0.9	776
3	Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncology, The, 2018, 19, 672-681.	10.7	732
4	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell, 2019, 35, 238-255.e6.	16.8	547
5	Choice of renal replacement therapy modality and dialysis dependence after acute kidney injury: a systematic review and meta-analysis. Intensive Care Medicine, 2013, 39, 987-997.	8.2	262
6	Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology, 2017, 28, 1130-1136.	1.2	253
7	Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Antiâ€“Programmed Cell Death 1 Antibodies. JAMA Oncology, 2018, 4, 717.	7.1	229
8	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nature Medicine, 2021, 27, 301-309.	30.7	218
9	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature Communications, 2019, 10, 3163.	12.8	205
10	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. Clinical Cancer Research, 2017, 23, 5024-5033.	7.0	192
11	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncology, The, 2019, 20, e378-e389.	10.7	155
12	Fluid resuscitation with 6Â% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Medicine, 2013, 39, 558-568.	8.2	147
13	A Randomized Controlled Trial of Regional Citrate Versus Regional Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Adults*. Critical Care Medicine, 2015, 43, 1622-1629.	0.9	146
14	FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Annals of Oncology, 2018, 29, 2115-2120.	1.2	131
15	Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIBâ€“C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncology, The, 2019, 20, 961-971.	10.7	126
16	Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. OncoImmunology, 2016, 5, e1214788.	4.6	123
17	Long-Term Survival and Dialysis Dependency Following Acute Kidney Injury in Intensive Care: Extended Follow-up of a Randomized Controlled Trial. PLoS Medicine, 2014, 11, e1001601.	8.4	117
18	Siteâ€specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with antiâ€“PDâ€1 therapy. Cancer, 2020, 126, 86-97.	4.1	113

#	Article	IF	Citations
19	The Bidirectional Relationship Between Pain Intensity and Sleep Disturbance/Quality in Patients With Low Back Pain. Clinical Journal of Pain, 2014, 30, 755-765.	1.9	107
20	Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2021, 22, 836-847.	10.7	104
21	Effect of Intensive Patient Education vs Placebo Patient Education on Outcomes in Patients With Acute Low Back Pain. JAMA Neurology, 2019, 76, 161.	9.0	101
22	Effect of a Computer-Guided, Quality Improvement Program for Cardiovascular Disease Risk Management in Primary Health Care. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 87-95.	2.2	98
23	A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).. Journal of Clinical Oncology, 2017, 35, 9508-9508.	1.6	98
24	Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. European Journal of Cancer, 2017, 75, 169-178.	2.8	96
25	Sleep-Deprived Young Drivers and the Risk for Crash. JAMA Pediatrics, 2013, 167, 647.	6.2	94
26	Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. British Journal of Cancer, 2017, 116, 1558-1563.	6.4	91
27	Fluid Resuscitation with 6% Hydroxyethyl Starch (130/0.4) in Acutely Ill Patients. Anesthesia and Analgesia, 2012, 114, 159-169.	2.2	85
28	Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. Journal of Clinical Oncology, 2020, 38, 2719-2727.	1.6	84
29	Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. Journal of Clinical Oncology, 2019, 37, 3132-3141.	1.6	78
30	Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Annals of Oncology, 2019, 30, 815-822.	1.2	77
31	Prognostic significance of postsurgery circulating tumor <scp>DNA</scp> in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. International Journal of Cancer, 2021, 148, 1014-1026.	5.1	77
32	Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Annals of Oncology, 2021, 32, 917-925.	1.2	76
33	Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas: A Breslow Thickness Cut Point of 0.8Âmm Separates Higher-Risk and Lower-Risk Tumors. Annals of Surgical Oncology, 2018, 25, 894-902.	1.5	69
34	Poor Sleep Quality Is Strongly Associated With Subsequent Pain Intensity in Patients With Acute Low Back Pain. Arthritis and Rheumatology, 2014, 66, 1388-1394.	5.6	62
35	A Trial of Extending Hemodialysis Hours and Quality of Life. Journal of the American Society of Nephrology: JASN, 2017, 28, 1898-1911.	6.1	62
36	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapyâ˜†. Annals of Oncology, 2020, 31, 1075-1082.	1.2	62

#	Article	IF	Citations
37	Comparison of radiation exposure of trauma patients from diagnostic radiology procedures before and after the introduction of a panscan protocol. EMA - Emergency Medicine Australasia, 2012, 24, 43-51.	1.1	57
38	Research Techniques Made Simple: Sample SizeÂEstimation and Power Calculation. Journal of Investigative Dermatology, 2018, 138, 1678-1682.	0.7	57
39	Rheumatic immune-related adverse events secondary to antiâ€“programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. European Journal of Cancer, 2018, 105, 88-102.	2.8	53
40	Combined ipilimumab and nivolumab firstâ€line and after BRAFâ€targeted therapy in advanced melanoma. Pigment Cell and Melanoma Research, 2020, 33, 358-365.	3.3	51
41	The Motorcycle Rider Behavior Questionnaire: Psychometric properties and application amongst novice riders in Australia. Transportation Research Part F: Traffic Psychology and Behaviour, 2014, 22, 126-139.	3.7	50
42	Accuracy of optical coherence tomography for the diagnosis of superficial basal cell carcinoma: a prospective, consecutive, cohort study of 168 cases. British Journal of Dermatology, 2016, 175, 1290-1300.	1.5	48
43	Hospital Quality Improvement Initiative for Patients With Acute Coronary Syndromes in China. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 217-226.	2.2	46
44	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
45	Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial. Critical Care, 2014, 18, R45.	5.8	44
46	Clinical Models to Define Response and Survival With Antiâ€“PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 2022, 40, 1068-1080.	1.6	43
47	Clinicopathologic features associated with efficacy and longâ€term survival in metastatic melanoma patients treated with <scp>BRAF</scp> or combined <scp>BRAF</scp> and MEK inhibitors. Cancer, 2015, 121, 3826-3835.	4.1	40
48	Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas. Laboratory Investigation, 2017, 97, 130-145.	3.7	40
49	Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. Journal of Clinical Oncology, 2017, 35, 1721-1729.	1.6	40
50	Timing of Renal Replacement Therapy and Patient Outcomes in the Randomized Evaluation of Normal Versus Augmented Level of Replacement Therapy Study*. Critical Care Medicine, 2014, 42, 1756-1765.	0.9	35
51	1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. Annals of Surgical Oncology, 2018, 25, 2541-2549.	1.5	35
52	Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. Journal of the National Cancer Institute, 2019, 111, 1314-1322.	6.3	35
53	Metastasisâ€specific patterns of response and progression with antiâ€<scp>PD</scp>â€1 treatment in metastatic melanoma. Pigment Cell and Melanoma Research, 2018, 31, 404-410.	3.3	34
54	Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. Pigment Cell and Melanoma Research, 2018, 31, 509-515.	3.3	34

#	Article	IF	Citations
55	Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).. Journal of Clinical Oncology, 2019, 37, 9503-9503.	1.6	34
56	Tumour gene expression signature in primary melanoma predicts long-term outcomes. Nature Communications, 2021, 12, 1137.	12.8	33
57	Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence: a systematic review and individual patient data meta-analysis. Nephrology Dialysis Transplantation, 2018, 33, 1017-1024.	0.7	32
58	Estimated risk of progression of lentigo maligna to lentigo maligna melanoma. Melanoma Research, 2020, 30, 193-197.	1.2	32
59	The risk of cancer in people with diabetes and chronic kidney disease. Nephrology Dialysis Transplantation, 2012, 27, 3337-3344.	0.7	31
60	The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. Journal of Cancer Survivorship, 2019, 13, 503-511.	2.9	31
61	Does an on-road motorcycle coaching program reduce crashes in novice riders? A randomised control trial. Accident Analysis and Prevention, 2016, 86, 40-46.	5.7	29
62	Early acidâ€“base and blood pressure effects of continuous renal replacement therapy intensity in patients with metabolic acidosis. Intensive Care Medicine, 2013, 39, 429-436.	8.2	28
63	Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and antiâ€PDâ€1 antibodies. Pigment Cell and Melanoma Research, 2019, 32, 553-563.	3.3	28
64	Subungual Melanoma of the Hand. Annals of Surgical Oncology, 2019, 26, 1035-1043.	1.5	28
65	A risk prediction model for the development of subsequent primary melanoma in a populationâ€based cohort. British Journal of Dermatology, 2020, 182, 1148-1157.	1.5	28
66	Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas. Journal of Clinical Oncology, 2021, 39, 1243-1252.	1.6	28
67	Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. European Journal of Cancer, 2022, 162, 22-33.	2.8	28
68	Healthâ€related quality of life in survivors of acute kidney injury: The <scp>P</scp>rolonged <scp>O</scp>utcomes <scp>S</scp>tudy of the <scp>R</scp>andomized <scp>E</scp>valuation of <scp>N</scp>ormal versusâ€...<scp>A</scp>ugmented <scp>L</scp>evel <scp>R</scp>eplacement <scp>T</scp>herapy study outcomes. Nephrology, 2015, 20, 492-498.	1.6	26
69	Femoral Access and Delivery of Continuous Renal Replacement Therapy Dose. Blood Purification, 2016, 41, 11-17.	1.8	26
70	Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.. Journal of Clinical Oncology, 2020, 38, 10005-10005.	1.6	26
71	Daily Protein Intake and Patient Outcomes in Severe Acute Kidney Injury: Findings of the Randomized Evaluation of Normal versus Augmented Level of Replacement Therapy (RENAL) Trial. Blood Purification, 2014, 37, 325-334.	1.8	25
72	Analysis of an electrical impedance spectroscopy system in shortâ€term digital dermoscopy imaging of melanocytic lesions. British Journal of Dermatology, 2017, 177, 1432-1438.	1.5	25

#	Article	IF	Citations
73	Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases. Pathology, 2019, 51, 39-45.	0.6	25
74	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Annals of Oncology, 2021, 32, 375-383.	1.2	25
75	Rational and design of a stepped-wedge cluster randomized trial evaluating quality improvement initiative for reducing cardiovascular events among patients with acute coronary syndromes in resource-constrained hospitals in China. American Heart Journal, 2015, 169, 349-355.	2.7	24
76	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 2020, 38, 1429-1441.	1.6	23
77	Behind the Wheel: Predictors of Driving Exposure in Older Drivers. Journal of the American Geriatrics Society, 2015, 63, 1137-1145.	2.6	22
78	Can the Alexander Technique improve balance and mobility in older adults with visual impairments? A randomized controlled trial. Clinical Rehabilitation, 2015, 29, 244-260.	2.2	22
79	Faster Blood Flow Rate Does Not Improve Circuit Life in Continuous Renal Replacement Therapy: A Randomized Controlled Trial. Critical Care Medicine, 2017, 45, e1018-e1025.	0.9	22
80	Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. , 2020, 8, e001488.		22
81	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. Annals of Oncology, 2021, 32, 766-777.	1.2	22
82	Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial. Genetics in Medicine, 2021, 23, 2394-2403.	2.4	22
83	Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 2022, 33, 968-980.	1.2	22
84	Robust and accurate inference for generalized linear models. Journal of Multivariate Analysis, 2009, 100, 2126-2136.	1.0	21
85	Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens. Annals of Surgical Oncology, 2019, 26, 25-32.	1.5	21
86	Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. JAMA Dermatology, 2021, 157, 166.	4.1	21
87	The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors. Contemporary Clinical Trials, 2018, 70, 106-116.	1.8	19
88	An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. Medical Journal of Australia, 2014, 201, 671-673.	1.7	18
89	A randomized trial to evaluate the effectiveness of an individual, education-based safe transport program for drivers aged 75 years and older. BMC Public Health, 2013, 13, 106.	2.9	17
90	A trauma quality improvement programme associated with improved patient outcomes: 21 years of experience at an Australian Major Trauma Centre. Injury, 2014, 45, 830-834.	1.7	17

#	Article	IF	Citations
91	Breslow Thickness Measurements of Melanomas Around American Joint Committee on Cancer Staging Cut-Off Points: Imprecision and Terminal Digit Bias Have Important Implications for Staging and Patient Management. Annals of Surgical Oncology, 2016, 23, 2658-2663.	1.5	17
92	Extranodal Spread is Associated with Recurrence and Poor Survival in Stage III Cutaneous Melanoma Patients. Annals of Surgical Oncology, 2017, 24, 1378-1385.	1.5	17
93	Angiotensinâ€converting enzyme inhibitor usage and acute kidney injury: A secondary analysis of ‹scp›RENAL‹/scp› study outcomes. Nephrology, 2014, 19, 617-622.	1.6	16
94	Emergency department clinical redesign, teamâ€based care and improvements in hospital performance: A time series analysis. EMA - Emergency Medicine Australasia, 2015, 27, 317-322.	1.1	16
95	Histological regression in melanoma: impact on sentinel lymph node status and survival. Modern Pathology, 2021, 34, 1999-2008.	5.5	16
96	A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial).. Journal of Clinical Oncology, 2019, 37, TPS9600-TPS9600.	1.6	16
97	Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. , 2022, 10, e004771.		16
98	Low Ambient Temperature and Intracerebral Hemorrhage: The INTERACT2 Study. PLoS ONE, 2016, 11, e0149040.	2.5	15
99	The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.. Journal of Clinical Oncology, 2018, 36, e21588-e21588.	1.6	15
100	FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. Annals of Oncology, 2022, 33, 99-106.	1.2	15
101	Robust small sample accurate inference in moment condition models. Computational Statistics and Data Analysis, 2012, 56, 3182-3197.	1.2	14
102	Understanding burn injuries in Aboriginal and Torres Strait Islander children: protocol for a prospective cohort study: TableÂ1. BMJ Open, 2015, 5, e009826.	1.9	14
103	Debate: adjuvant whole brain radiotherapy or not? More data is the wiser choice. BMC Cancer, 2016, 16, 372.	2.6	14
104	Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. Cancer, 2020, 126, 4717-4725.	4.1	14
105	Predicting sentinel node positivity in patients with melanoma: external validation of a riskâ€prediction calculator (the Melanoma Institute Australia nomogram) using a large European populationâ€based patient cohort*. British Journal of Dermatology, 2021, 185, 412-418.	1.5	14
106	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer, 2021, 153, 168-178.	2.8	14
107	Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12â€month followâ€up results of a randomized controlled trial. British Journal of Dermatology, 2020, 182, 860-868.	1.5	13
108	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. Cancer Immunology Research, 2020, 8, 1346-1353.	3.4	13

#	Article	IF	Citations
109	The prognostic significance of microsatellites in cutaneous melanoma. Modern Pathology, 2020, 33, 1369-1379.	5.5	13
110	A multicentre study of naevusâ€associated melanoma vs. de novo melanoma, tumour thickness and body site differences*. British Journal of Dermatology, 2021, 185, 101-109.	1.5	13
111	An adaptive confirmatory trial with interim treatment selection: Practical experiences and unbalanced randomization. Statistics in Medicine, 2011, 30, 1541-1554.	1.6	12
112	On the maximum penalized likelihood approach for proportional hazard models with right censored survival data. Computational Statistics and Data Analysis, 2014, 74, 142-156.	1.2	12
113	Falls in Older people with Cataract, a longitudinal evalUation of impact and riSk: the FOCUS study protocol: TableÂ1. Injury Prevention, 2014, 20, e7-e7.	2.4	12
114	A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy. Melanoma Research, 2017, 27, 243-250.	1.2	12
115	Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, 9532-9532.	1.6	12
116	Trends in fall-related ambulance use and hospitalisation among older adults in NSW, 2006â€“2013: a retrospective, population-based study. Public Health Research and Practice, 2017, 27, .	1.5	12
117	Prognostic Significance of Periadnexal Extension in Cutaneous Melanoma and its Implications for Pathologic Reporting and Staging. American Journal of Surgical Pathology, 2018, 42, 359-366.	3.7	11
118	Behind the Wheel. Transportation Research Record, 2015, 2516, 35-43.	1.9	10
119	MULTIPLE ways to correct for MULTIPLE comparisons in MULTIPLE types of studies. British Journal of Dermatology, 2021, 185, 1081-1083.	1.5	10
120	The Honeypot Randomized Controlled Trial Statistical Analysis Plan. Peritoneal Dialysis International, 2013, 33, 426-435.	2.3	9
121	Epidemiology of RBC Transfusions in Patients With Severe Acute Kidney Injury. Critical Care Medicine, 2016, 44, 892-900.	0.9	9
122	3302 Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma. European Journal of Cancer, 2015, 51, S664.	2.8	8
123	Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions. British Journal of Dermatology, 2017, 177, 574-577.	1.5	8
124	Effects of pulsed low-frequency magnetic field therapy on pain intensity in patients with musculoskeletal chronic low back pain: study protocol for a randomised double-blind placebo-controlled trial. BMJ Open, 2019, 9, e024650.	1.9	8
125	Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. Annals of Surgical Oncology, 2021, 28, 6109-6123.	1.5	8
126	Utility of 1-year FDG-PET (PET) to determine outcomes from anti-PD-1 (PD1) based therapy in patients (pts) with metastatic melanoma (MM).. Journal of Clinical Oncology, 2018, 36, 9517-9517.	1.6	8

#	Article	IF	Citations
127	An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial. Implementation Science, 2015, 11, 129.	6.9	7
128	Impact of the Alexander technique on wellâ€being: a randomised controlled trial involving older adults with visual impairment. Australasian journal of optometry, The, 2017, 100, 633-641.	1.3	7
129	Communities driving change: evaluation of an Aboriginal driver licensing programme in Australia. Health Promotion International, 2018, 33, 925-937.	1.8	7
130	Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. British Journal of Surgery, 2021, 108, 550-553.	0.3	7
131	An electronic decision supportâ€based complex intervention to improve management of cardiovascular risk in primary health care: a cluster randomised trial (INTEGRATE). Medical Journal of Australia, 2021, 214, 420-427.	1.7	7
132	Surgical excision margins in primary cutaneous melanoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2021, 47, 1558-1574.	1.0	7
133	Re-induction ipilimumab following acquired resistance to combination ipilimumab and antiâ€“PD-1 therapy. European Journal of Cancer, 2021, 153, 213-222.	2.8	7
134	3305 PD1 inhibition-induced changes in melanoma and its associated immune infiltrate. European Journal of Cancer, 2015, 51, S666.	2.8	6
135	Accurate pâ€values for adaptive designs with binary endpoints. Statistics in Medicine, 2017, 36, 2643-2655.	1.6	6
136	Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance. Radiation Oncology, 2018, 13, 132.	2.7	6
137	FRAMe: Familial Risk Assessment of Melanomaâ€”a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma. Familial Cancer, 2021, 20, 231-239.	1.9	6
138	A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy.. Journal of Clinical Oncology, 2019, 37, 9502-9502.	1.6	6
139	Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. , 2022, 10, e004610.		6
140	External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. British Journal of Surgery, 2019, 106, 1319-1326.	0.3	5
141	Primary dermal melanoma: clinical behaviour, prognosis and treatment. European Journal of Surgical Oncology, 2020, 46, 2131-2139.	1.0	5
142	The Melanoma Genomics Managing Your Risk Study randomised controlled trial: statistical analysis plan. Trials, 2020, 21, 594.	1.6	5
143	Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. European Journal of Surgical Oncology, 2021, 47, 1145-1151.	1.0	5
144	A randomized, placebo-controlled trial of patient education for acute low back pain (PREVENT Trial): statistical analysis plan. Brazilian Journal of Physical Therapy, 2017, 21, 219-223.	2.5	4

#	Article	IF	Citations
145	Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan. Trials, 2019, 20, 477.	1.6	4
146	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. European Journal of Cancer, 2022, 167, 123-132.	2.8	4
147	Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. Annals of Surgical Oncology, 2022, 29, 5937-5945.	1.5	4
148	Saddlepoint approximation for semi-Markov processes with application to a cardiovascular randomised study. Computational Statistics and Data Analysis, 2009, 53, 683-698.	1.2	3
149	Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs).. Journal of Clinical Oncology, 2019, 37, 9500-9500.	1.6	3
150	The progressive relationship between increasing Breslow thickness and decreasing survival is lost in patients with ultrathick melanomas (â‰¥15Âmm in thickness). Journal of the American Academy of Dermatology, 2022, 87, 298-305.	1.2	3
151	Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients. European Journal of Cancer, 2022, 167, 133-141.	2.8	3
152	Change in the Hippocampal Volume After Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance Technique. International Journal of Radiation Oncology Biology Physics, 2015, 93, E82.	0.8	2
153	Reply to M. Horiguchi et al. Journal of Clinical Oncology, 2018, 36, 722-723.	1.6	2
154	Predicting Sentinel Node Status in Patients With Melanoma: Does Gene Expression Profiling Improve Accuracy?. JCO Precision Oncology, 2020, 4, 990-991.	3.0	2
155	Residual melanoma in wide local excision specimens after â€˜completeâ€™ excision of primary cutaneous in situ and invasive melanomas. Pathology, 2022, 54, 71-78.	0.6	2
156	Adaptive designs for clinical trials have potential advantages, but statistical challenges lurk!. British Journal of Dermatology, 2022, 186, 205-206.	1.5	2
157	Protocol for the implementation of a stepped-care model to address fear of cancer recurrence in patients previously diagnosed with early-stage (0â€“II) melanoma. BMJ Open, 2022, 12, e054337.	1.9	2
158	Penalized likelihood estimation of a mixture cure Cox model with partly interval censoringâ€”An application to thin melanoma. Statistics in Medicine, 2022, , .	1.6	2
159	The Association Between Excision Margins and Local Recurrence in 1407 Patients with Primary In Situ Melanomas. JAAD International, 2022, , .	2.2	2
160	Semiparametric methods for multistate survival models in randomised trials. Statistics in Medicine, 2014, 33, 1621-1645.	1.6	1
161	Perceived Value of a Motorcycle Training Program: The Influence of Crash History and Experience of the Training. Traffic Injury Prevention, 2014, 15, 407-413.	1.4	1
162	ASO Author Reflections: Long-Term Survival of Patients with Thin (T1) Cutaneous Melanomas. Annals of Surgical Oncology, 2018, 25, 918-919.	1.5	1

#	Article	IF	Citations
163	Combined ipilimumab and nivolumab first-line and after BRAF-directed targeted therapies in advanced melanoma patients. Annals of Oncology, 2018, 29, viii448.	1.2	1
164	The ABC of reporting statistical analyses in theBJD: Always Be Clear. British Journal of Dermatology, 2018, 179, 3-5.	1.5	1
165	Comment on â€œPrognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanomaâ€• Journal of the American Academy of Dermatology, 2019, 80, e21-e22.	1.2	1
166	Sentinel lymph node biopsy remains the most accurate method of obtaining staging and prognostic information for patients with primary cutaneous melanomas. Australasian Journal of Dermatology, 2019, 60, 75-76.	0.7	1
167	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. European Journal of Cancer, 2021, 153, 8-15.	2.8	1
168	Sustained long-term benefits of a psycho-educational intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: A randomised controlled trial.. Journal of Clinical Oncology, 2018, 36, 10082-10082.	1.6	1
169	Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. Australasian Journal of Dermatology, 2022, 63, .	0.7	1
170	Targeting the neonatal Fc receptor in pemphigus: safety first. British Journal of Dermatology, 2022, 186, 389-390.	1.5	1
171	Same-day or next-day sentinel node biopsy after lymphoscintigraphy for melanoma using Tc-labelled antimony sulphide colloid. British Journal of Surgery, 2020, 107, 1773-1779.	0.3	1
172	57â€…Driving change: implementation of a multi-site community licensing program for aboriginal people. Injury Prevention, 2016, 22, A22.2-A22.	2.4	0
173	Outcome and Prognostic Factors of Stereotactic Radiosurgery (SRS) for Melanoma Brain Metastases (MBM) in Era of Effective Systemic Therapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, E710-E711.	0.8	0
174	521â€…Does an on-road motorcycle coaching program reduce crashes in novice riders? A randomised control trial. Injury Prevention, 2016, 22, A188.1-A188.	2.4	0
175	Blood flow rate and circuit life in continuous renal replacement therapy (CRRT): a randomised controlled trial (RCT). Australian Critical Care, 2017, 30, 109.	1.3	0
176	The survivorship experience of patients with metastatic melanoma on long-term immune checkpoint inhibitors. Annals of Oncology, 2018, 29, ix105.	1.2	0
177	Pragmatic trials: lab meets bedside. British Journal of Dermatology, 2019, 181, 431-433.	1.5	0
178	Phase 3 International Trial of Adjuvant Whole Brain Radiotherapy (WBRT) or Observation (OBS) Following Local Treatment of 1-3 Melanoma Brain Metastases (MBMs). International Journal of Radiation Oncology Biology Physics, 2019, 105, S139-S140.	0.8	0
179	Quality of Life Following Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA Dermatology, 2019, 155, 502.	4.1	0
180	Author response to: Comment on: External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma. British Journal of Surgery, 2020, 107, 616-616.	0.3	0

#	Article	IF	Citations
181	Survivorship experience for patients (pts) with metastatic melanoma (MM) on immunotherapy (IT).. Journal of Clinical Oncology, 2018, 36, e21503-e21503.	1.6	0
182	Survivorship experience for patients (pts) with metastatic melanoma (MM) on long-term targeted therapy (TT).. Journal of Clinical Oncology, 2018, 36, 9556-9556.	1.6	0
183	Competing risks analysis with missing cause-of-failureâ€"penalized likelihood estimation of cause-specific Cox models. Statistical Methods in Medical Research, 2022, , 096228022110702.	1.5	0
184	Effect of the <scp>SunSafe</scp> Training Program on the attitudes, knowledge, and behaviour of Australian high school students towards sun safety: a prospective study. Clinical and Experimental Dermatology, 2022, , .	1.3	0
185	Sensitivity of two Australian melanoma risk tools to identify highâ€risk individuals among people presenting with their first primary melanoma. Australasian Journal of Dermatology, 2022, , .	0.7	0
186	A tool to predict survival outcomes and guide adjuvant immunotherapy recommendations for patients with stage II melanoma.. Journal of Clinical Oncology, 2022, 40, e21556-e21556.	1.6	0
187	A biomarker-guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP) trial design.. Journal of Clinical Oncology, 2022, 40, TPS9599-TPS9599.	1.6	0